Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown promise in
reducing the risk of atrial fibrillation (AF). However, the results are controversial and the …

Gemigliptin-Rosuvastatin single-pill combination is a promising therapeutic tool in the
effective control of hyperglycemia and hypercholesterolemia. Organic sensors with high …

Diabetic atherosclerosis is a complex process that is characterized by diffuse and unstable
lesions increasing 2–4-fold the risk of adverse cardiovascular (CV) events. Diabetic …

Background Whether the cardiovascular treatment benefits of sodium–glucose co-
transporter 2 inhibitors (SGLT-2is) and glucagon-like peptide 1 receptor agonists (GLP …

Type 2 diabetes mellitus (T2DM) management and glycemic control in underserved non-
Hispanic Black adults presents with multifaceted challenges: balancing the optimal …

Cardiovascular disease (CVD) remains a prominent cause of global mortality, primarily
driven by atherosclerosis. Diabetes mellitus, as a modifiable risk factor, significantly …

Aims We aim to investigate the causal effect of blood lipids mediating sodium‐glucose
cotransporter 2 (SGLT2) inhibition in cardiovascular disease (CVD) using Mendelian …

Background Doxorubicin (DOX) is used to treat various types of cancers. However, its use is
restricted by cardiotoxicity, a leading cause of morbidity and mortality. Glucagon-like peptide …

Despite the risk of atherosclerosis has progressively declined over the past few decades,
subjects with type 2 diabetes mellitus (T2DM) continue to experience substantial excess of …

Abstract Introduction: Elevated lipoprotein (a)[Lp (a)] is independently associated with an
increased risk of cardiovascular disease (CVD). Objectives: Evaluating the levels of Lp (a) …